Morgan Stanley Aerie Pharmaceuticals Inc Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $4.28 Million - $10.2 Million	-671,191 Reduced 33.71%	1,319,893 $20 Million
Q2 2022 Oct 27, 2022	SELL	$4.95 - $9.16 $5.73 Million - $10.6 Million	-1,156,985 Reduced 36.75%	1,991,084 $14.9 Million
Q2 2022 Aug 15, 2022	SELL	$4.95 - $9.16 $5.73 Million - $10.6 Million	-1,156,985 Reduced 36.75%	1,991,084 $14.9 Million
Q1 2022 Oct 27, 2022	BUY	$5.64 - $9.8 $6.53 Million - $11.3 Million	1,156,985 Added 58.11%	3,148,069 $28.6 Million
Q1 2022 May 13, 2022	SELL	$5.64 - $9.8 $4.98 Million - $8.66 Million	-883,486 Reduced 21.91%	3,148,069 $28.6 Million

Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $12.7 Million - $24.1 Million	1,811,319 Added 81.58%	4,031,555 $28.3 Million
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $25.1 Million - $36.9 Million	2,220,236 New	2,220,236 $25.3 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.